


PHARMACEUTICAL 2019

Viking Therapeutics Inc. Rank 29 of 371





PHARMACEUTICAL 2019



Viking Therapeutics Inc. Rank 29 of 371

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 213% points. The greatest weakness of Viking Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 155%, being 486% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	302,133
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,550
Liabilities, Non-Current	12
Other Assets	179
Other Compr. Net Income	-403
Other Expenses	0
Other Liabilities	0
Other Net Income	4,098
Property and Equipment	0
Research and Development	19,040
Revenues	0
Selling, General and Administrative Expense	7,121

Output Variable	Value in 1000 USD
Assets	302,312
Liabilities	4,562
Expenses	26,161
Stockholders Equity	297,750
Net Income	-22,063
Comprehensive Net Income	-22,264
Economic Capital Ratio	155%